The device, which is delivered transapically, represents an option for very sick patients who previously have had none.

Reaching participants through retail pharmacies, the study speaks to how much VHD goes underrecognized—with a few surprises.

The data are largely in line with those seen at 5 years, but the follow-up reassures there’s no concern about valve ...

The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.

Operators are excited about a device that avoids transapical access, a limitation of other systems, says Gilbert Tang.